BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
See today's BioWorld Asia
Home
» Zai has arrived; inks deal with Sanofi for preclinical COPD drugs
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Zai has arrived; inks deal with Sanofi for preclinical COPD drugs
Aug. 20, 2014
By
Shannon Ellis
No Comments
SHANGHAI – Newly minted Zai Lab Ltd., of Shanghai, has made its eagerly awaited debut announcement, obtaining global rights to two Sanofi SA preclinical compounds for chronic respiratory diseases.
BioWorld Asia